30 March 2023 | Thursday | News
Under Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscopes and related systems and equipment, this cooperation further broadens its market penetration of its Single-Use Percutaneous Choledochoscope. Through the strong alliance with Boston Scientific, the penetration rate of the Single-Use Percutaneous Choledochoscope in China is expected to increase benefiting more hospitals and patients.
Scivita Medical said, 'Thanks to Boston Scientific for its recognition of Scivita Medical. This is another important initiative for Scivita Medical in establishing its vision of becoming a global company, and another milestone following its strategic cooperation with Fujifilm for the European market. I believe this strategic cooperation with some of the world's leading medical technology companies and our company will accelerate the process of bringing China's medical innovations to the world.'
As a result of the growing demands of mitigating the risks of cross-contamination and hospital-acquired diseases, particularly amid the outbreak of COVID-19 pandemic, the global single-use videoscope market is also rapidly growing. The global market value of single-use videoscope was USD 0.5 billion in 2020, and is estimated to increase to USD 9.2 billion in 2030, according to Frost & Sullivan. Scivita Medical's single-use videoscopes have covered multiple clinical departments at a high risk of cross-infection, such as Gynecology, Respiratory, Urological Surgery and Hepatobiliary Surgery. Many of its products have already been approved in China, the United States, European Union (EU), Japan and other countries and regions.
This cooperation can be seen as strong evidence of Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscope and related systems and equipment, which further accelerates its commercialization and penetration in the field of single-use videoscope. In the future, Scivita Medical will further strengthen its innovation, improve market penetration by offering unique products and strive to become the preferred brand for doctors and patients worldwide.
© 2024 Biopharma Boardroom. All Rights Reserved.